What are the treatment guidelines for pediatric hemophagocytic lymphohistiocytosis (HLH)?

Treatment Guidelines for Pediatric Hemophagocytic Lymphohistiocytosis

The HLH-94 protocol remains the consensus standard of care for pediatric HLH, consisting of dexamethasone, etoposide, cyclosporine A, and intrathecal therapy in selected cases, with hematopoietic stem cell transplantation (HSCT) recommended for familial disease or severe/persistent cases. 1, 2

Core Treatment Protocol

The HLH-94/2004 protocol has dramatically improved outcomes in pediatric HLH from nearly uniformly fatal to long-term survival >50% 1. This protocol specifically targets activated T cells and suppresses inflammatory cytokine production through:

• Dexamethasone 10 mg/m²
• Etoposide 150 mg/m² (typically twice weekly initially)
• Cyclosporine A (CSA) - can be started upfront or after 8 weeks
• Intrathecal therapy with methotrexate and corticosteroids (only if progressive neurological symptoms after 2 weeks or abnormal CSF not improving) 1, 2

The initial 8-week treatment course should be followed by weekly reevaluation to determine if continued etoposide is necessary 1. Patients with residual disease after 8 weeks benefit from maintenance therapy and potentially HSCT 1.

Risk-Stratified Approach for Secondary HLH

Recent evidence supports stratified treatment intensity based on disease severity, particularly for secondary HLH which predominates in Asian populations 3, 4:

Low-risk patients (based on cytokine levels and clinical criteria):

• May achieve sustained remission with dexamethasone monotherapy alone (32.4% of patients in one cohort) 4
• 5-year overall survival of 96.9% with reduced chemotherapy intensity 3

High-risk patients (severe disease, organ failure, or deterioration):

• Require immediate full HLH-94 protocol with etoposide 4
• Etoposide should not be delayed in rapidly deteriorating patients 1

Infection Prophylaxis - Critical for Mortality Reduction

Broad antimicrobial prophylaxis is mandatory during HLH treatment due to severe immunosuppression 1:

• Pneumocystis jirovecii prophylaxis (required)
• Antifungal prophylaxis (required)
• Antiviral prophylaxis (strongly recommended due to severe T-cell depletion)
• Consider hospitalization in HEPA-filtered units 1

Secondary infections are a major cause of fatality during chemotherapy, making this prophylaxis non-negotiable 1.

EBV-Associated HLH

For EBV-triggered HLH, treatment intensity depends on clinical severity 1, 4:

Severe/rapidly deteriorating patients:

• Immediate etoposide-based HLH-94 protocol
• Consider adding rituximab 375 mg/m² weekly for 2-4 doses to clear EBV reservoir in B cells 1

Less severe or improving patients:

• Short course of corticosteroids ± IVIG may suffice
• Monitor ferritin, sCD25, cell counts, and EBV DNA levels (>10³ copies/mL is significant) 1

Hematopoietic Stem Cell Transplantation

HSCT is recommended for 1, 2:

• All patients with familial/primary HLH (genetic mutations confirmed)
• Severe and persistent disease after initial therapy
• Reactivated disease

Inactive HLH before transplantation is strongly associated with better survival - achieve disease control first 1. Reduced-intensity conditioning (RIC) has shown favorable outcomes in children compared to myeloablative conditioning 1.

Emerging Therapies for Refractory Disease

For relapsed/refractory HLH not responding to standard therapy 5, 6, 7:

Emapalumab (anti-IFN-γ antibody):

• Higher starting doses (7.2 mg/kg vs 1.7 mg/kg) achieve faster remission (median 14 vs 28 days) 7
• Consider combination with JAK inhibitors for increased efficacy 7

Other options:

• Alemtuzumab (anti-CD52)
• Ruxolitinib (JAK1/2 inhibitor)
• Anakinra (IL-1 inhibitor) - particularly for macrophage activation syndrome 1, 5

Critical Pitfalls to Avoid

1. Do not delay etoposide in severe disease - imminent organ failure requires immediate administration 1

2. Adjust etoposide for renal impairment (primarily renally cleared), but no dose reduction needed for isolated liver dysfunction 1

3. Stay below cumulative etoposide dose of 2-3 g/m² to avoid secondary malignancy risk 1

4. Do not use etoposide sparingly in "HLH during chemotherapy" - bone marrow recovery is essential for immune reconstitution; prioritize corticosteroids and IVIG instead 1

5. Identify and treat the underlying trigger - treatment must address both hyperinflammation and the precipitating cause (infection, malignancy, autoimmune disease) 1

Monitoring Parameters

Weekly assessment should include:

• Ferritin levels
• Soluble CD25 (sCD25)
• Complete blood counts
• Liver function
• For EBV-HLH: EBV DNA viral load 1

The 5-year overall survival for pediatric HLH with modern stratified protocols is 86.3%, with primary HLH having lower survival (72.9%) compared to secondary HLH (89.0%) 3.